| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/13/2000 | WO2000015208A3 New use of immunosupressants for mmp-mediated diseases |
| 07/13/2000 | WO2000015175A3 Use as an active substance of molecules binding to beta-1-integrin with the capacity to kill cells |
| 07/13/2000 | WO2000013683A3 Novel nitrophenylaziridine compounds and their use as prodrugs |
| 07/13/2000 | WO2000010958A9 Vitamin d3 mimics |
| 07/13/2000 | WO2000009734A9 Methods and compositions for use in spliceosome mediated rna trans-splicing |
| 07/13/2000 | WO2000003737A9 Water-soluble drugs and methods for their production |
| 07/13/2000 | WO1999060142A3 Gene therapy vectors and their use in antitumour therapy |
| 07/13/2000 | WO1999058096A9 Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis |
| 07/13/2000 | WO1997020575A8 Targeted adenovirus vectors |
| 07/13/2000 | DE19933939A1 Ausnutzung zelleigener Transportsysteme zum Transfer von Nukleinsäuren durch die Kernhülle Utilization of cellular transport systems for the transfer of nucleic acids by the nuclear envelope |
| 07/13/2000 | DE19900743A1 Neue komplexbildende Proteine New complexing proteins |
| 07/13/2000 | DE19900673A1 Verwendung von Bindungspartnern für 5-HT5-Rezeptoren zur Behandlung neurodegenerativer und neuropsychiatrischer Störungen Use of binding partners for 5-HT5 receptors for the treatment of neurodegenerative and neuropsychiatric disorders |
| 07/13/2000 | DE19900503A1 Verwendung einer Zusammensetzung zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen mit erhöhten extrazellulären FasL-Titern, Verfahren zur prophylaktischen Eignungs- bzw. Qualitätskontrolle derselben, Verfahren zur Herstellung von Arzneimitteln zur Behandlung obiger Krankheiten mit gesteigerter Wirksamkeit Use of a composition for the manufacture of a medicament for the treatment of diseases with increased extracellular FasL titers method for the prophylactic or suitability quality control thereof, a process for the preparation of medicaments for the treatment of the above diseases with enhanced efficacy |
| 07/13/2000 | CA2753331A1 Soluble receptor br43x2 and methods of using |
| 07/13/2000 | CA2358939A1 3-(thio-substituted amido)-lactams useful as inhibitors of matrix metalloproteinase |
| 07/13/2000 | CA2358754A1 Synergistic tumorcidal response induced by histamine |
| 07/13/2000 | CA2358495A1 Prolonged release microsphere encapsulating luteinizing hormone-releasing hormone analogues and method for preparing the same |
| 07/13/2000 | CA2358430A1 Potentiation of anti-cd38-immunotoxin cytotoxicity |
| 07/13/2000 | CA2358427A1 Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13 |
| 07/13/2000 | CA2358119A1 Compositions and methods relating to cyclic compounds that undergo nucleotide base pair-specific interactions with double-stranded nucleic acids |
| 07/13/2000 | CA2357986A1 Acid stable backbone modified end-blocked nucleic acids and therapeutic uses thereof |
| 07/13/2000 | CA2357950A1 Therapeutic phosphodiesterase inhibitors |
| 07/13/2000 | CA2357874A1 Cyclic compound |
| 07/13/2000 | CA2357146A1 Human cyclic nucleotide pdes |
| 07/13/2000 | CA2356966A1 Amidomalonamides and their use as inhibitors of matrix metalloproteinase |
| 07/13/2000 | CA2356937A1 Recombinant herpes simplex virus useful for treating neoplastic disease |
| 07/13/2000 | CA2356919A1 Selective inhibitors of mmp-12 |
| 07/13/2000 | CA2356447A1 Use of adenosine agonists in cancer therapy |
| 07/13/2000 | CA2356434A1 Non-myeloablative tolerogenic treatment |
| 07/13/2000 | CA2356368A1 Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents |
| 07/13/2000 | CA2355967A1 Astrocytes, their preparation and uses thereof |
| 07/13/2000 | CA2355859A1 Gene therapy-1 |
| 07/13/2000 | CA2355302A1 Colchinol derivatives as vascular damaging agents |
| 07/13/2000 | CA2354638A1 Expression of secreted human alpha-fetoprotein in transgenic animals |
| 07/13/2000 | CA2354194A1 Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells |
| 07/12/2000 | EP1018560A1 Vectors for treating cancer |
| 07/12/2000 | EP1018555A2 Chimeric papilomavirus-like particles |
| 07/12/2000 | EP1018518A2 Use of autoantibodies for tumor therapy and prophylaxis |
| 07/12/2000 | EP1017854A1 Documentation means for repertoires of nkr immunoreceptors and/or activatory or non-inhibitory immunoreceptor counterparts of nkr immnunoreceptors |
| 07/12/2000 | EP1017838A2 Expression of genes in hematopoietic stem cells in hischaemic conditions |
| 07/12/2000 | EP1017835A1 Methods of using cytochrome p450 reductase for the enhancement of p450-based anti-cancer gene therapy |
| 07/12/2000 | EP1017826A2 Compositions and methods for identifying pkb kinase inhibitors |
| 07/12/2000 | EP1017823A2 Engineered protein kinases which can utilize modified nucleotide triphosphate substrates |
| 07/12/2000 | EP1017817A2 Mutants of thyroid stimulating hormone and methods based thereon |
| 07/12/2000 | EP1017815A1 Murine model for human carcinoma |
| 07/12/2000 | EP1017810A1 Agonist and antagonist peptides of carcinoembryonic antigen (cea) |
| 07/12/2000 | EP1017809A2 Human regulatory molecules |
| 07/12/2000 | EP1017808A2 53bp2 complexes |
| 07/12/2000 | EP1017800A1 Antisense oligonucleotides against thymidylate synthase |
| 07/12/2000 | EP1017723A2 Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use |
| 07/12/2000 | EP1017720A1 Site-directed chemotherapy of metastases |
| 07/12/2000 | EP1017697A1 MODULES OF PROTEIN TYROSINE PHOSPHATASES (PTPases) |
| 07/12/2000 | EP1017685A1 New 2-(3h)-oxazolone derivatives |
| 07/12/2000 | EP1017682A1 Novel angiogenesis inhibitors |
| 07/12/2000 | EP1017678A1 1,5-diphenylpyrazole derivatives |
| 07/12/2000 | EP1017675A1 Highly lipophilic camptothecin derivatives |
| 07/12/2000 | EP1017672A1 New npy antagonists |
| 07/12/2000 | EP1017423A1 Cloning pigs using donor nuclei from differentiated cells |
| 07/12/2000 | EP1017419A1 Fucosyl gm1-klh conjugate vaccine against small cell lung cancer |
| 07/12/2000 | EP1017418A1 Vaccine composition for preventing or treating c hepatitis |
| 07/12/2000 | EP1017412A1 Genes coding proteins for early liver development and their use in diagnosing and treating liver disease |
| 07/12/2000 | EP1017407A2 Useful properties of human lactoferrin and variants thereof |
| 07/12/2000 | EP1017406A1 Bovine excretion extracts having anticancer and anti-inflammatory activity and process for preparing the same |
| 07/12/2000 | EP1017399A1 Camptothecin analogs and methods of preparation thereof |
| 07/12/2000 | EP1017394A1 Cyclin dependent kinase inhibiting purine derivatives |
| 07/12/2000 | EP1017387A1 Vitronectin receptor antagonist |
| 07/12/2000 | EP1017385A1 USE OF 4-SUBSTITUTED TETRAHYDROPYRIDINES FOR MAKING MEDICINES ACTING ON TGF-beta 1 |
| 07/12/2000 | EP1017384A1 Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function |
| 07/12/2000 | EP1017283A1 Polynucleotide vaccine formulations |
| 07/12/2000 | EP0918545B1 Tumour therapy |
| 07/12/2000 | EP0745073B1 5-substituted derivatives of mycophenolic acid |
| 07/12/2000 | EP0413762B1 Peptide analogs and their use as haptens to elicit catalytic antibodies |
| 07/12/2000 | CN1259998A Modified retinoblastoma tumor suppressor protein |
| 07/12/2000 | CN1259962A Anti-vegf antibodies |
| 07/12/2000 | CN1259961A Humanized antibodies and method for forming same |
| 07/12/2000 | CN1259959A GnRh antagonists being modified in positions 5 and 6 |
| 07/12/2000 | CN1259950A Pyrrolo [2,3D] pyrimidines and their use as tyrosine kinase inhibitors |
| 07/12/2000 | CN1259947A 2-aryl-naphthyridin-4-ones as antitumor agent |
| 07/12/2000 | CN1259945A Prevention of breast cancer with selective estrogen receptor modulators |
| 07/12/2000 | CN1259944A Treatments of prophylaxis of prostatic cancer and benign prostatic hyperplasia |
| 07/12/2000 | CN1259940A Crystalline roxifiban |
| 07/12/2000 | CN1259938A Crambescidin compound |
| 07/12/2000 | CN1259875A Pharmaceutical compositions contg. anti-body-enzyme conjugates in combination with prodrugs |
| 07/12/2000 | CN1259869A Pharmaceutical compositions contg. cinchonine dichlorhydrate |
| 07/12/2000 | CN1259868A Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for treating cancer |
| 07/12/2000 | CN1259867A Use of bis-1,2,4-triazoles for mfg. medicament for treating cancers |
| 07/12/2000 | CN1259864A Rapamycin formulations for oral administration |
| 07/12/2000 | CN1259385A Arsenic, enzyme compound medicine and prepn. for directly applied on cancer focus and prepn. method thereof |
| 07/12/2000 | CN1259377A Guang Ye He Huan albizia anticancer medicine and its prepn. method |
| 07/12/2000 | CN1259367A Traditional Chinese medicinal pill for transforming calculus, eliminating toxin and anti tumour |
| 07/12/2000 | CN1259353A Animal cartilage health-care capsule for inhibiting tumour growth, eliminating free radical and anti peroxidation of lipid and prepn. method thereof |
| 07/12/2000 | CN1054381C Taxane having antitumor activity, mfg. method and pharmaceutical compositions thereof |
| 07/12/2000 | CN1054373C Full fluoralkyl-substituted bezoylguanidine prepn. pharmaceutical use of same and pharmaceutical containing same |
| 07/12/2000 | CN1054298C Medicine for treating gastropathy and esophagus cancer |
| 07/12/2000 | CN1054289C Medicine for curing tumour |
| 07/12/2000 | CN1054288C Application plaster for treating cancer pain |
| 07/12/2000 | CN1054286C Medicine for relieving inflammation and pain |
| 07/11/2000 | US6087509 Derivatives of trifluorobenzonitriles |
| 07/11/2000 | US6087505 Benzo[1,2-G]-chrom-3-ene, and benzo[1,2-G]-thiochrom-3-ene derivatives |
| 07/11/2000 | US6087392 (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides |